Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18403395 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
Condition: Immune Thrombocytopenic Purpura
Intervention: Drug: Rituximab and dexamethasone

Indicates status has not been verified in more than two years